AR060565A1 - Vacuna para la gripe aviaria y metodos de uso - Google Patents

Vacuna para la gripe aviaria y metodos de uso

Info

Publication number
AR060565A1
AR060565A1 ARP070101721A ARP070101721A AR060565A1 AR 060565 A1 AR060565 A1 AR 060565A1 AR P070101721 A ARP070101721 A AR P070101721A AR P070101721 A ARP070101721 A AR P070101721A AR 060565 A1 AR060565 A1 AR 060565A1
Authority
AR
Argentina
Prior art keywords
methods
vaccine
aviary
flu
vaccines
Prior art date
Application number
ARP070101721A
Other languages
English (en)
Spanish (es)
Original Assignee
Dow Agrosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc
Publication of AR060565A1 publication Critical patent/AR060565A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP070101721A 2006-04-21 2007-04-20 Vacuna para la gripe aviaria y metodos de uso AR060565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79380406P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
AR060565A1 true AR060565A1 (es) 2008-06-25

Family

ID=39402309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101721A AR060565A1 (es) 2006-04-21 2007-04-20 Vacuna para la gripe aviaria y metodos de uso

Country Status (9)

Country Link
US (1) US7993655B2 (enExample)
EP (1) EP2010210A4 (enExample)
JP (1) JP2009535306A (enExample)
KR (1) KR20080109094A (enExample)
CN (1) CN101578111A (enExample)
AR (1) AR060565A1 (enExample)
BR (1) BRPI0710689A2 (enExample)
CA (1) CA2650091A1 (enExample)
WO (1) WO2008060669A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713671A2 (pt) 2006-06-16 2013-12-03 Dow Agrosciences Llc Sequências de dna, vetores e proteínas de hemaglutinina de influenza aviária
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
US9408902B2 (en) 2007-05-30 2016-08-09 Samuel Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN103122354B (zh) 2007-11-27 2018-03-23 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
US8771703B2 (en) 2008-07-08 2014-07-08 Medicago Inc. Soluble recombinant influenza antigens
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
WO2010123519A1 (en) * 2009-04-23 2010-10-28 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
CA2762042C (en) 2009-06-24 2012-11-20 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
WO2011079282A1 (en) * 2009-12-23 2011-06-30 Vaxgene Corporation Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules
HRP20171564T1 (hr) 2009-09-22 2017-11-17 Medicago Inc. Postupak za pripremu biljnih čestica sličnih virusu (vlp)
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
EP2734226A2 (en) 2011-07-20 2014-05-28 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
AU2013204906B2 (en) * 2012-03-12 2016-01-07 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
BR102013032129B1 (pt) 2012-12-13 2022-06-07 Dow Agrosciences Llc Método para identificar a presença de um polinucleotídeo de dna doador exógeno inserido dentro de um único locus genômico eucariótico alvo

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173410A (en) 1984-02-15 1992-12-22 Lubrizol Genetics Inc. Transfer vector
US4885248A (en) 1984-02-15 1989-12-05 Lubrizol Genetics, Inc. Transfer vector
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
ES2060646T3 (es) 1987-02-09 1994-12-01 Lubrizol Genetics Inc Virus rna hibrido.
EP0506763B1 (en) 1989-12-22 1999-06-02 E.I. Du Pont De Nemours And Company Site-specific recombination of dna in plant cells
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
JPH07200893A (ja) 1993-12-27 1995-08-04 Toshiba Corp 自動精算機
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
JP2000253876A (ja) 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
AU5714601A (en) * 2000-04-19 2001-10-30 Univ Johns Hopkins Methods for prevention and treatment of gastrointestinal disorders
WO2002008386A2 (en) 2000-07-20 2002-01-31 The University Of Tennessee Research Corporation Materials and methods for the enhancement of effective root nodulation in legumes
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
DE10061150A1 (de) 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10109354A1 (de) 2001-02-27 2002-09-05 Icon Genetics Ag Rekombinante virale Schaltersysteme
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
CA2450019A1 (en) 2001-06-08 2002-12-19 Icon Genetics, Inc. Production of proteins in plants
DE10129010A1 (de) 2001-06-13 2002-12-19 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10143205A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Verfahren zur Proteinproduktion in Pflanzen
AU2002319157B2 (en) 2002-04-29 2008-01-03 Bayer Cropscience N.V. Process of producing environmentally safe transgenic organisms
JP2007526215A (ja) * 2003-05-05 2007-09-13 ダウ アグロサイエンス リミテッド ライアビリティー カンパニー トランスジェニック植物細胞に由来する安定な免疫予防的および治療的組成物ならびにその産生方法
DE602004028004D1 (de) * 2003-05-05 2010-08-19 Thompson Boyce Plant Res Vektoren und zellen zur herstellung von aus transgenen pflanzen gewonnenen immunprotektiven zusammensetzungen
CA2816222A1 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
DE602004027403D1 (de) 2003-11-10 2010-07-08 Icon Genetics Ag Von rna-virus abgeleitetes pflanzenexpressionssystem

Also Published As

Publication number Publication date
EP2010210A4 (en) 2010-07-21
BRPI0710689A2 (pt) 2012-02-22
US7993655B2 (en) 2011-08-09
WO2008060669A3 (en) 2009-05-07
WO2008060669A2 (en) 2008-05-22
JP2009535306A (ja) 2009-10-01
CA2650091A1 (en) 2008-05-22
CN101578111A (zh) 2009-11-11
US20090136532A1 (en) 2009-05-28
EP2010210A2 (en) 2009-01-07
KR20080109094A (ko) 2008-12-16

Similar Documents

Publication Publication Date Title
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
CR9551A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
MX2018009917A (es) Vacuna contra el virus del zika.
MX381718B (es) Agentes biologicos y su uso en plantas.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CO6880050A2 (es) Composiciones y metodos para controlar la fusariosis
IT1397734B1 (it) Uso di estratti naturali di tannini e non tannini atti a migliorare la fertilita' del suolo e determinare un effetto starter sulle colture, e fitocomplesso di tannini e di non tannini per tale uso.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
EA201070219A1 (ru) Полимерные мультиэпитопные вакцины против гриппа
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CL2008002727A1 (es) Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos
UY36395A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
GT201100145A (es) Vacuna recombinante para influenza aviar y sus usos
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
ECSP099066A (es) Vacuna combinada estreptococica
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
AR087811A1 (es) Vacuna contra el staphylococcus aureus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal